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Abstract:	 Graft-versus-host	 disease	 (GVHD)	 is	 a	 major	 complication	 of	 allogeneic	 hematopoietic	 stem	 cell	
transplants	 (allo-HSCT)	 associated	with	 significant	morbidity	 and	mortality.	 The	 earliest	 and	most	 common	
manifestation	is	cutaneous	graft-versus-host	disease.	This	review	focuses	on	the	pathophysiology,	clinical	features,	
prevention and treatment of cutaneous graft-versus-host disease. We discuss various insights into the disease’s 
mechanisms and the different treatments for acute and chronic skin graft-versus-host disease.
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INTRODUCTION
Graft-versus-host	disease	(GVHD)	is	common-
ly observed after allogeneic hematopoietic stem cell 
transplants	 (allo-HSCT),	but	rarely	after	 transfusions	
or solid organ transplants. 1	GVHD	 is	a	major	 cause	
of	 morbidity	 and	 mortality,	 affecting	 40-60%	 of	 al-
lo-HSCT	recipients,	and	accounting	for	15%	of	deaths	
following this procedure.2 Clinical manifestations of 
GVHD	after	HSCT	transplantation	include:	fever,	cu-
taneous	 rash,	 severe	 gastrointestinal	 manifestations	
and impaired liver function.
The earliest and most common manifestation is 
cutaneous	GVHD	and	some	authors	have	found	that	it	
entails a worse prognosis.3 Lesions usually start on the 
pinnae	and	neck	and	progress	to	confluent	lesions	on	
the	cheeks,	upper	trunk,	palms	and	soles,	which	may	
become	generalized.4 Patients may complain of pruri-
tus or tenderness in affected areas. The onset of rashes 
normally correlates with engraftment of donor cells.
This article seeks to provide a brief overview of 
cutaneous	GVHD,	its	clinical	manifestations,	diagnos-
tic	methods,	treatments	and	prognosis	depending	on	
evolution.
CUTANEOUS GRAFT VERSUS-HOST 
DISEASE
GVHD	remains	 a	 significant	 cause	of	morbid-
ity and mortality in allogeneic hematogeneic HSCT 
recipients.	 It	 is	 defined	 as	 a	 syndrome	 in	which	 im-
munocompetent	donor	cells	recognize	and	attack	host	
tissues in an immunocompromised recipient.5 The risk 
of	GVHD	increases	with	the	use	of	unrelated	donors,	
mismatched	donors,	older	donors,	mutliparous	female	
donors,	older	recipients,	some	graft	types	and	certain	
conditoning regimens.6
Acute	graft	versus	host	disease	 (aGvHD)	gen-
erally occurs after allogeneic hematopoietic HSCT. It 
is a reaction of donor immune cells against host tis-
sues.	The	revised	National	Institute	for	Health	(NIH)	
criteria	now	define	classic	aGvHD	as	occurring	with-
in	100	days	 following	HSCT;	and	 late	onset	aGvHD,	
which entails typical signs and symptoms but occurs 
after	100	days,	affecting	mainly	the	skin,	gastrointesti-
nal tract and liver.7 Acute	GVHD	is	stage	clinically	by	
the number and extent of organ involvement. Chronic 
graft-versus-host	 disease	 (cGVHD)	 occurs	 100	 days	
after	HSCT,	representing	50%	of	all	cases	and	causing	
An Bras Dermatol. 2016;91(3):336-43.
late	mortality	 in	up	 to	 25%	of	 patients.	 It	 is	 defined	
using the NIH criteria.8
One of the earliest and most common manifes-
tations	of	GVHD	is	cutaneous	GVHD,	which	consists	
essentially of a maculopapular rash that can begin any-
where in the body but often starts with palm and sole 
involvement. Early lesions are usually centered on a 
hair	follicle,	a	clue	for	diagnosis.9 Erythematous macu-
lopapular rashes are characteristic and tend to appear 
10-30 days after transplantation. The skin is staged 
with percent of body surface area involved and der-
matologists have traditionally used the International 
Bone	 Marrow	 Transplant	 Registry	 (IBMTR)	 grading	
system,	which	tries	to	diminish	inter-observer	variabil-
ity	in	GVHD	evaluation.10	Skin	GVHD	grade	I	involves	
a maculopapular rash of < 25% of body surface area 
(BSA);	grade	II	entails	a	maculopapular	rash	of	25–50%	
BSA;	 grade	 III	 is	 typified	 by	 a	 maculopapular	 rash	
of	>	50%	BSA;	while	grade	 IV	denotes	a	generalized	
erythroderma plus bullous formation. Table 1 synthe-
tizes	different	grading	systems	for	cutaneous	GVHD.
PATHOPHYSIOLOGY AND HISTOLOGY
To	dermatologists,	knowledge	of	pathophysiol-
ogy	and	the	main	histopathological	findings	of	GVHD	
is	 crucial.	 For	GVHD	 to	occur,	 the	donor	graft	must	
contain immunologically competent cells and the host 
must be incapable of mounting an effective immune 
response	to	destroy	the	transplanted	cells.	In	addition,	
the host must express tissue antigens that are not pres-
ent in the transplant donor. 11
It is well-known that the interactions between 
chemokines and their receptors have an important 
role	 in	 initiating	 GVHD	 after	 allo-HSCT.12 Recent 
studies have shown that the migration of lympho-
cytes	to	secondary	lymphoid	tissues	or	target	organs,	
such	as	the	skin,	liver	and	gut,	is	regulated	by	specif-
ic	 chemokines,	which	 regulate	 the	 trafficking	of	 leu-
kocytes through interactions with a subset of seven 
transmembrane,	G	 protein-coupled	 receptors.13 Their 
interactions thus play an important role in provoking 
organ-specific	GVHD.
Histologically,	 the	 condition	 entails	 vacuolar	
degeneration	 of	 the	 basal	 cell	 layer,	 dyskeratotic	 ke-
ratinocytes	 and	mild,	mononuclear,	 superficial,	 peri-
vascular	infiltrate.	Furthermore,	epithelial	damage	oc-
curs,	initially	at	the	tips	of	rete	ridges	and	hair	follicles	
(Figures	1	and	2).14 These	findings	suggest	the	follow-
ing pathogenic mechanism: activated donor lympho-
cytes attack and destroy recipient keratinocytes. This 
inflammatory	 infiltrate	 is	 mainly	 composed	 of	 CD4	
and CD8 lymphocytes. 15
Table 1:	Histopathology	described	by	Lerner	et	al.	for	diagnosing	GvHD.	1994	Consensus	Conference	on	Acute	
GVHD	Grading,	focusing	on	Skin	GVHD	and	International	Bone	Marrow	Transplant	Registry	(IBMTR)	staging	
of	GVHD
Histopathology described by Lerner et al. for 
diagnosing GVHD (27)
Grade Skin
0 Normal skin
1	 	Mild	vacuolization	of	epidermal	cells
2	 	Diffuse	vacuolization	of	basal	cells	
with scattered dyskeratotic bodies
3  Sub-epidermal cleft formation
4  Complete epidermal separation
1994 Consensus Conference on Acute 
GVHD Grading. (54)
Stage Skin
0	 No	GVHD	rash
1	 Maculopapular	rash<	25%	BSA
2	 	Maculopapular	rash	25	–	50%	BSA
3	 Maculopapular	rash	>	50%	BSA
4	 	Generalized	erythroderma	plus	
bullous formation
International Bone Marrow Transplant 
Registry (IBMTR)
Grade GVHD
I	 Skin	stage	1–2
II Skin stage 3 or liver/gut stage I
III  Skin Stage 3 or liver stage 2-3/
gut stage 2-4
IV	 Skin	stage	4	or	liver	stage	4
 
*BSA:	Body	surface	area;	GVHD:	Graft-versus-host	disease.
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FIgure 1:	Histological	aspects	of	cutaneous	GVHD.	Skin	biopsy	of	
cutaneous	GVHD:	hyperkeratosis,	hypergranulosis	associated	with	
lichenoid	inflammatory	infiltrate	is	observed.	(10X,	HyE)
Risk	 factors	 for	 acute	 cutaneous	 GVHD	 have	
been	described,	including:	a	diagnosis	of	chronic	my-
eloid	leukaemia,	HLA	disparity,	receipt	of	more	than	
one	 HSCT,	 conditioning	 regimens	 including	 total	
body	 irradiation,	 and	 GVHD	 prophylaxis	 regimens	
other than ciclosporin plus methotrexate.16 This group 
of patients (patients with all the risk factors described 
above) should me monitorated closely to detect early 
sings	of	cutaneaos	GVHD.
CLINICAL MANIFESTATIONS
Acute	cutaneous	graft-versus	host	disease	usu-
ally	presents	with	a	pruritic	and	painful	rash,	approx-
imately	2-3	weeks	after	HSCT.	Clinically,	on	physical	
examination,	a	morbilliform	exanthem	usually	mani-
fests,	with	red	to	violaceous	lesions,	 initially	appear-
ing	on	the	palms,	soles,	cheeks,	neck,	ears,	and	upper	
trunk	(Figures	3	and	4).	The	rash	may	spread	around	
the	 entire	 body	 and,	 if	 severe,	 vesicles,	 bullae,	 and	
erythroderma	 can	 develop.	 Generalized	 desquama-
tion also emerges.17
Chronic	 GvHD	 (c-GVHD)	 is	 the	 most	 com-
mon	 complication	 after	 transplantation,	 reported	 in	
60–80%	of	patients.	The	 skin	 is	 affected	 in	over	90%	
of	 cases,	 often	 resulting	 in	 long-term	 complications	
such	 as	 cosmetic,	 functional,	 and	 even	 life-threaten-
ing	disorders	and	sequelae.	14 Since this chronic entity 
involves	a	wide	spectrum	of	manifestations,	we	will	
expand further on its clinical aspects. The cutaneous 
involvement of this entity has traditionally been di-
vided into two forms: limited and extensive.14 How-
ever,	dermatologists	have	long	recognized	two	stages	
in	cGvHD:	lichenoid	cGvHD,	appearing	early	on;	and	
sclerodermatous	cGvHD,	manifesting	later.18 The his-
tological	picture	of	lichenoid	GVHD	is	similar	to	that	
of	 classic	 lichen	planus:	hyperkeratosis,	hypergranu-
losis,	 acanthosis	 and	dyskeratotic	keratinocytes	with	
basal	cell	vacuolization.19 A	moderate	to	marked,	ban-
dlike	 infiltrate	 along	 the	 dermal	 epidermal	 junction,	
occasionally	extending	to	the	deep	dermis,	is	essential	
for	 diagnosis,	 as	 vacuolar	 degeneration	 of	 the	 basal	
cell	layer	is	a	common,	long-lasting	finding	in	patients	
after allo-HSCT. 20
Sclerodermatous	 GVHD	 can	 affect	 every	 skin	
level.	 In	 lichen	 sclerosus,	 epidermal	 atrophy,	 edema	
and	homogenization	of	the	collagen	in	the	upper	der-
mis	are	usual	findings.20 In	morphoea	lesions,	there	are	
three	collagen	sclerosis	patterns:	pandermal,	patched	
FIgure 2:	Histological	aspects	of	cutaneous	GVHD.	Skin	biopsy	of	
cutaneous	GVHD:	Epidermal	Basal	cell	apoptosis	associated	with	
melanin pigment deposits are present near the basement membrane 
zone.	(40X,	HyE)
FIgure 3:	Clinical	manifestations	of	cutaneous	GVHD.	Patient	with	
GVHD	grade	3,	maculopapular	erythematous	rash	affecting	the	an-
terior portion of thorax and extremities
FIgure 4:	Clinical	manifestations	of	cutaneous	GVHD.	Patient	with	
GVHD	 grade	 3,	 maculopapular	 erythematous	 rash	 affecting	 the	
posterior portion of thorax
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and deep dermal. Histological changes involving pan-
niculitis	with	fibrosis	and	fasciitis	are	also	frequent.21
Importantly,	sclerodermatous	GvHD	is	preced-
ed	by	lichenoid	lesions	only	in	40%	of	cases,	and	not	all	
patients with lichenoid GvHD progress to the sclero-
dermatous	phase,	which	is	associated	with	bad	prog-
nosis	and	is	the	last	stage	of	cutaneous	GvHD,	usually	
occurring	subsequently	to	day	500	after	AHSCT. 22
Clinically,	 lichenoid	 graft-versus-host	 disease	
patients present with violaceous or erythematous pap-
ules	and	plaques,	including	a	fine	scale	on	top	that	can	
coalesce.	It	frequently	starts	on	the	trunk	and	becomes	
generalized	a	few	weeks	later,	although	in	some	cases	
lesions	remain	 localized.	Furthermore,	 it	 is	preceded	
by	scattered	hyperpigmented	macules	 (leopard	skin)	
and keratosis pilaris.20 The sclerosis presents in the 
form	 of	 lichen	 sclerosus,	 morphoea	 and/or	 ripply	
skin,	correlating	with	the	histological	level	of	sclerot-
ic involvement.23 Bullous	 lesions,	 ulcers,	 poikiloder-
matous	 changes,	 pyogenic	 granuloma-like	 lesions,	
subcutaneous	 tissue	 eventrations,	 anetoderma	 and	
pigmentary	 changes,	 can	 all	 be	 found.20 Special fol-
low-up should be given to these patients with cutane-
ous	involvement,	given	the	risk	of	joint	retraction	and	
diminished mobility.
Special consideration should be extended to 
patients treated with a reduced intensity condition 
regimen	 (RIC).	 This	 conditioning	 regimen	 is	 being	
used	 in	developing	countries,	with	positive	respons-
es.	Unlike	myeloablative	 regimens,	RIC	 schemes	 are	
associated	with	a	decreased	release	of	pro-inflamma-
tory	 cytokines,	due	 to	 limited	 tissue	damage	during	
their	administration,	as	well	as	a	transient	and	poten-
tially tolerogenic state of mixed donor/host chime-
rism.24 These differences might account for the lower 
rates of severe GvHD after unrelated HSCT with a 
non-myeloablative	RIC,	as	compared	to	myeloablative	
conditioning.25
Patients	 receiving	 reduced	 intensity	 regimens,	
which	do	not	result	in	marrow	ablation,	often	have	a	
later	onset	of	GVHD.	This	is	due	both	to	the	later	en-
graftment and the damage from the preparative regi-
men,	producing	cytokines	that	drive	the	immune	re-
sponses,	thus	resulting	in	clinical	GVHD.	As	the	rash	
progresses,	it	may	become	confluent.	In	severe	cases,	
blisters	may	occur.	Consequently,	dermatologists	have	
greater contact with these patients at their clinics.
DIAGNOSIS
Cutaneous	 GVHD	 is	 usually	 suspected	 based	
on	the	clinical	presentation.	A	biopsy	can	be	used	to	
confirm	the	diagnosis	and	should	be	used	when	there	
are	competing	diagnoses,	such	as	infection	and	drug	
reaction,	 in	 the	 differential.	 These	 skin	 biopsies	 can	
reveal	dyskeratotic	keratinocytes,	 lymphocyte	exocy-
tosis,	basal	cell	necrosis,	depletion	of	Langerhans	cells,	
and satellite lymphocytes next to the dyskeratotic ke-
ratinocytes.	Importantly,	not	all	the	findings	necessar-
ily feature in every skin biopsy and histology is not 
always pathognomonic.26
The aformentioned grading system for diagnos-
ing GvHD is based on the histopathology by Lerner et 
al.:	Grade	0	±	normal	skin,	Grade	I	±	mild	vacuoliza-
tion	of	epidermal	cells,	Grade	 II	±	diffuse	vacuoliza-
tion	of	basal	cells	with	scattered	dyskeratotic	bodies,	
Grade	III	±	sub-epidermal	cleft	formation	and	Grade	
IV	 ±	 complete	 epidermal	 separation.27 A	 skin	 biopsy	
may	be	considered	if	eruptions	suggesting	GVHD	de-
velop	during	early	stages	after	HSCT.	Significantly,	bi-
opsies	in	GVHD	are	not	pathognomic	and	usually	not	
necessary	to	diagnose	cutaneous	GVHD.
TREATMENT
Cutaneous	 involvement	 is	 the	 most	 frequent	
manifestation	of	GVHD	and	dermatologists	should	be	
aware	of	the	clinical	signs	of	aGVHD	to	treat	it	as	early	
as possible.
Glucocorticoids	remain	the	first-line	therapy	for	
patients	who	develop	acute	GVHD,	often	in	combina-
tion	with	other	agents	such	as	antithymocyte	globulin,	
CsA,	 tacrolimus,	 MMF	 or	 monoclonal	 antibodies.28 
However,	 only	 20-40%	 of	 patients	 show	 a	 durable	
response.29 A	major	side	effect	of	systemic	glucocorti-
coids is an increased risk of infection and relapse of 
the underlying malignancy.30 Second-line treatments 
or salvage therapy should be started if: the disease 
progresses	after	3	days,	there	is	no	change	after	7	days	
or the response is incomplete after 14 days of cortico-
steroid therapy.31
Topical immunosuppressive therapies for 
cGVHD	are	linked	to	less	toxicity	compared	with	sys-
temic treatment. Their use can improve response rates 
and	 thus,	 facilitate	 dose	 reduction,	 reduce	 toxicity	
or even help circumvent the application of systemic 
drugs	 in	 cases	 of	 mild	 cGVHD.	 Topical	 calcineurin	
inhibitors are of special interest on anatomical sites 
such	as	the	face	or	intertriginous	areas,	where	potent,	
topical steroids should be used with caution.32 The 
advantage topical pimecrolimus has over tacrolimus 
is its improved local tolerability. It is preferred in the 
treatment	of	mild	 cGVHD,	 facial	manifestations	and	
for children.
Alternative	therapies	are	available	for	these	pa-
tients.	Although	 hematopoietic	 cell	 transplanted	 pa-
tients are counseled to avoid ultraviolet radiation due 
to	possible	GVHD	flare	or	increased	risk	of	skin	can-
cer,	psoralens	plus	ultraviolet	A	light	(PUVA)	or	nar-
row band-ultraviolet B phototherapy are the treatment 
choices	for	sclerotic	cGVHD	lesions.	The	action	mecha-
nisms of phototherapy include antiproliferative effects 
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as	well	 as	 immunomodulation,	 influencing	 cytokine	
production,	 cell	 activation,	 antigen	presentation	 and	
apoptosis of various cells including T lymphocytes.33 
The	 longer	 the	 radiation	wavelength,	 the	deeper	 the	
skin	absorption:	UVB	is	primarily	absorbed	in	the	epi-
dermis,	whereas	UVA	penetrates	more	deeply	into	the	
dermis. Some of the phototherapies currently used to 
treat cutaneous GvHD will be outlined.
EXTRACORPOREAL PHOTOPHERESIS
Significant	 improvement	 has	 been	 reported	
in	patients	with	 chronic	 cutaneous	GVHD	 (cGVHD)	
after treatment with extracorporeal photopheresis 
(ECP).34 The	procedure	involves	peripheral	blood	(PB)	
leucocytes being isolated from the patient and irradi-
ated	with	UVA	light	in	combination	with	a	photo-sen-
sitizing	 agent	 such	 as	 psoralens.	 This	 can	 be	 taken	
orally by the patient 2 hours before the procedure or 
added directly to the buffy coat bag containing the 
leucocyte-rich fraction.35 ECP is known to affect cy-
tokine release and changes in Th1/ Th2 ratios might 
explain	some	of	its	therapeutic	benefits.36 In exclusive-
ly	cutaneous	lichenoid	cGVHD,	extracorporeal	photo-
phoresis has proven to be the most effective therapy.18 
Regarding patients with sclerodermatous graft-ver-
sus-host	disease,	etretinate	and	extracorporeal	photo-
phoresis are the most effective treatments.18 Recently,	
imatinib was found to be useful in several cases.37 
Some	 major	 complications	 of	 extracorporeal	
photopheresis	can	occur,	usually	 involving	 the	 long-
term	 indwelling	 central	 venous	 apheresis	 catheters,	
which are needed to maintain the long-term vascular 
access	 required	 for	 treatment,	 transient	 hypotension	
during	 the	procedure,	post-reinfusion	 fever	and	ery-
thema and nausea related to oral psoralen ingestion.38
UVA-1 PHOTOTHERAPY
UVA-l	 phototherapy	 induces	 apoptosis	 of	
skin-infiltrating	 T	 cells,	 thus	 causing	 a	 gradual	 re-
duction	 of	 the	 inflammatory	 infiltrate.39 In	 addition,	
radiation is a potent inducer of the immunosuppres-
sive cytokine interleukin 10 in human keratinocytes. 
Furthermore,	a	dose-dependent	upregulation	of	colla-
genase	activity	has	been	reported,	which	could	be	re-
sponsible for the clinical improvement seen in patients 
with scleroderma.40 UVA-l	 is	 usually	 well-tolerated,	
with	very	 few	 side	 effects.	 Erythema,	 tanning,	poly-
morphic	light	eruptions,	ilching	and	recrudescence	of	
the herpes simplex infection are the main acute ad-
verse	 effects.	 UVA-1	 also	 has	 significant	 advantages	
over	PUVA,	as	 it	avoids	nausea,	vomiting,	 long-last-
ing skin photosensitivity and the need for eye protec-
tion.	Moreover,	 PUVA	 therapy	 often	 fails	 and	 is	 not	
well-tolerated by patients since it can cause local pain 
and blistering. 41
As	 primary	 therapy	 for	 acute	 GVHD	 of	 the	
skin,	UVA-1	 treatment	 is	 feasible,	well-tolerated	and	
effective	 in	 an	 outpatient	 setting,	 irrespective	 of	 age	
or conditioning regimen type. Systemic steroids can 
thus be avoided and/or tapered more rapidly in some 
patients.	 Nevertheless,	 patients	 must	 be	 monitored	
carefully for early detection of possible secondary cu-
taneous malignancies.42
UVA-1	irradiation	seems	to	be	a	suitable	and	ef-
fective primary treatment option in all patients with 
acute	GVHD	of	the	skin,	regardless	of	the	condition-
ing regimen type. The impact of RICs on the incidence 
and	 severity	of	 acute	GVHD,	and	on	 its	 response	 to	
treatment,	has	not	been	evaluated	 in	depth.	Patients	
with RICs demonstrated a later median onset of acute 
GVHD	compared	with	non-RIC	patients.	Further,	pa-
tients	with	RICs	required	more	treatment	sessions	and	
a	 higher	 median	 dose	 of	 UVA-1	 irradiation	 to	 treat	
acute	GVHD	of	 the	 skin	 than	patients	with	non-RIC	
HCT. This may be due to their lower production of 
tumor	 necrosis	 factor-a,	 increased	 T-regulatory	 cell	
numbers and delayed emergence of activated donor 
DC,	unlike	non-RIC	patients.42,43
A	major	 concern	surrounding	UVA	treatments	
and	the	secondary	effects	is	the	potentially	long-term,	
carcinogenic	influence	of	UVA-1	(315–400nm)	therapy,	
though	UVB	radiation	(wavelength	band	280–315nm)	
is regarded as the most carcinogenic modality.44 How-
ever,	malignant	melanoma	development	is	considered	
unrelated	to	UVA	irradiation,	while	melanoma	risk	is	
not	associated	with	cumulative,	but	rather	with	more	
intensive	and	intermittent,	exposure	to	sunlight.45
SKIN TRASNPLANTATION
In cases of skin ulceration due to refractory 
chronic	 cutaneous	GVHD	 after	 allo-HSCT,	 there	 are	
few reports in the literature about treatment with skin 
transplantation.	J	Ammer	et	al.	reported	a	case	of	re-
fractory	treatment	in	patients	with	chronic	GVHD	after	
allo-HSCT. The report described successful treatment 
of a patient via split-thickness skin transplantation 
from	the	HLA-identical	donor.46 In	1985,	Knobler	et	al.	
published one of the earliest reports on treatment for 
ulcerating	 chronic	GVHD	using	 skin	grafts	 from	 the	
BM donor.47 Another	three	studies	reported	successful	
allogeneic	skin	grafting	in	severe	chronic	GVHD	from	
the	HLA-identical	stem	cell	donor.48 Recently,	a	French	
cohort treated a patient for extensive ulcerating cuta-
neous	GVHD,	with	a	two-step	skin	transplantation	of	
the	HLA-identical	sister,	resulting	in	complete	cover-
age	of	the	skin	lesion	and	subsequent	withdrawal	of	
immunosuppression.49 Table 2 summarizes	the	differ-
ent	treatments	available	for	skin	GVHD.
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FOLLOW-UP RECOMENDATIONS
Besides the different aforementioned treat-
ments,	there	are	recommendations	to	be	considered	for	
these patients during follow-up. Regular lubrication is 
mandatory	 to	 maintain	 skin	 integrity.	 Moisturizers,	
urea	 (3–10%)	 and	 glycerol	 in	 particular	 are	 hydrat-
ing	and	help	to	regenerate	the	injured	transepidermal	
lipid barrier. Dermatological examination of skin and 
mucous membranes every 12 months is highly recom-
mended. In patients with a history of cutaneous ma-
lignancies,	the	screening	interval	should	be	shortened	
to	at	least	6	months,	with	an	offer	of	special	evaluation	
for	potential	cutaneous	infection.	After	withdrawal	of	
immunosuppression,	cutaneous	examinations	should	
be continued every year.31 Dermatoscopic screening 
should	also	be	included,	as	melanoma	risk	is	signifi-
cantly elevated in patients following HSCT. 50
Table 2:	Current	treatments	available	for	skin	GVHD.	Description	of	treatment	uses	and	adverse	effects	is	provided
Treatment General characteristics
Steroids	 	•		Immunosuppressive	medications,	used	to	prevent	acute	GVHD	alone	or	in	combination	with	other	agents	such	as	
ATG,	CSA,	tacrolimus,	MMF	or	monoclonal	antibodies.
 •  Only 20-40% of patients show a durable response.
	 	•		Side	effects:	Increased	risk	of	infection	and	of	relapse	of	the	underlying	malignancy,	skin	atrophy.
 •  Sort by potency:
	 	 I.	Mild	(lower-potency	steroid):	Hydrocortisone	0.1–14
	 	 II.	Moderate	(mid-potency	steroid):	Triamcinolone	acetonide	0.05–0.1%
	 	 III.	Potent	(high-potency	steroid):	Mometasone	furoate	0.1%
	 	 IV.	Very	potent	(ultra-high-potency	steroid):	Clobetasol	propionate	0.05%
Extracorporeal	 •		Glucocorticoid-refractory	acute	and	chronic	GVHD
photopheresis	 •		Peripheral	blood	leucocytes	are	isolated	from	the	patient	and	irradiated	with	UVA	light	in	combination	with	a	pho-
to-sensitizing	agent	such	as	psoralens.
	 •		Cytokine	release	and	changes	in	Th1/Th2	ratios	might	explain	some	of	its	therapeutic	benefits.
	 •		Side	effects:	hypotension	during	the	procedure,	post-reinfusion	fever	and	erythema	and	nausea	related	to	oral	pso-
ralen ingestion.
UVA-l	 •		Induces	apoptosis	of	skin-infiltrating	T	cells,	thereby	causing	a	gradual	reduction	of	the	inflammatory	infiltrate.
phototherapy •  Dose-dependent up-regulation of collagenase activity.
	 •		Highly	effective	in	treating	acute	cutaneous	GVHD	with	an	overall	response	rate	of	94.3%.
	 •		Feasible,	well-tolerated	and	effective	in	treating	chronic	as	well	as	acute	GVHD.
 •  This form of phototherapy is currently not widely available.
	 •		Few	side	effects:	Erythema,	tanning,	polymorphic	light	eruptions,	recrudescence	of	herpes	simplex	infection.
 •  Potential long-term adverse effect: carcinogenic.
Skin	 •		Alternative	in	cases	of	skin	ulceration	due	to	refractory	chronic	cutaneous	GVHD.
transplantation	 •		Split-thickness	transplantation	from	the	HLA-identical	donor.
CONCLUSION
We conclude that due to the increasing inci-
dence	of	hematological	diseases,	more	accessible	con-
ditioning	regimens	like	RICs	in	developing	countries,	
and	the	new	HSCT	modalities,	hematopoietic	stem	cell	
transplantation is now a common therapy worldwide. 
As	explained,	GVHD	is	highly	prevalent	in	patients	re-
ceiving a HSCT; skin GvHD is the most common man-
ifestation following HSCT. It can appear as an acute 
or	chronic	comorbidity,	and	it	affects	greatly	patients’	
quality	of	life.	Thus,	it	is	essential	for	dermatologists	to	
know	the	different	aspects	of	skin	GVHD,	as	well	as	its	
proper	diagnosis,	prevention	and	treatment.q
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